# Pevion Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pevion-biotech

- Industry: Biotechnology
- Headquarters: Bern, Switzerland
- Website: www.pevion.com
- Total disclosed funding: $40M
- Latest round: Series B (Sep 7, 2010)
- Investors on record: 4

## About

Pevion Biotech AG is a Swiss biotechnology firm focused on developing innovative therapeutic solutions, particularly advanced vaccines designed to combat infectious diseases and enhance public health outcomes.Pevion Biotech AG specializes in the development of therapeutic solutions for infectious diseases. Founded in 2002, the company is headquartered in Bern, Switzerland. In September 2010, Pevion raised CHF 10 million through Series B financing from investors including BB Biotech, BZ Bank, and Core Capital Partners. The company has completed two significant funding rounds to date.Pevion specializes in the development of innovative therapeutic solutions focused on addressing significant healthcare challenges, particularly in the field of infectious diseases. Their core offerings include advanced vaccines designed to elicit robust immune responses, primarily targeting viral infections. These vaccines undergo a rigorous development process, leveraging cutting-edge technology to enhance efficacy and safety. Pevion's products are designed for administration in clinical settings, aiming to serve a diverse client base that includes healthcare providers, hospitals, and pharmaceutical companies. Geographically, Pevion's products are marketed in regions with a significant demand for advanced healthcare solutions, including Europe and North America, where there is a strong emphasis on preventive healthcare measures.Pevion generates revenue through strategic partnerships and collaborations with healthcare organizations and distributors. The company operates primarily on a business-to-business (B2B) model, engaging in transactions that involve the supply of its vaccine products to hospitals and clinics. Revenue is structured around agreements that include bulk purchases and long-term supply contracts, allowing clients to secure necessary quantities of vaccines for their patient populations. Pricing structures are based on the product's development and manufacturing costs, alongside competitive market analysis, ensuring that the offerings remain accessible while reflecting their advanced technology. The firm's flagship vaccines are integral to their revenue generation strategy.Pevion Biotech AG aims to leverage the CHF 10 million raised in Series B financing to support the development of new vaccine products targeting infectious diseases. The company plans to expand its market presence in Europe and North America, focusing on regions with increased healthcare demands by 2015. The recent funding will facilitate the ramp-up of product development and enhance marketing efforts to reach potential clients in these new markets.

## Funding rounds

- Series B, Sep 7, 2010, $9.9M — BB Biotech, Core Capital Partners, BZ Bank
- Series A, Aug 10, 2007, $30M — BB Biotech, Core Capital Partners, BZ Bank, Bachem Holding

## Investors

- BB Biotech (https://capitalatlas.ai/funds/bb-biotech) — Series A, Series B
- Core Capital Partners — Series A, Series B
- BZ Bank — Series A, Series B
- Bachem Holding — Series A